P-Cadherin Monoclonal Antibody (CSTEM29), eBioscience™, Invitrogen™

Description

This monoclonal antibody CSTEM29 reacts with human P-Cadherin, also known as Cadherin-3. Applications Reported: This CSTEM29 antibody has been reported for use in flow cytometric analysis and immunoblot. Applications Tested: This CSTEM29 antibody has been tested by flow cytometric analysis of normal human induced pluripotent stem cells, and for western blot. For flow cytometry, this may be used at less than or equal to 0.25 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. For western blot, this can be used at less than or equal to 10 μg/mL. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 μm post-manufacturing filtered.

P-cadherin, also known as Cadherin-3, is a Type 1 cadherin protein that belongs to the cadherin superfamily. Type 1 cadherins are single-pass transmembrane proteins that have 5 extracellular cadherin repeats and an intracellular domain that binds p120-catenin and beta-catenin. Cadherins are calcium-dependent cell-cell adhesion glycoproteins responsible for a range of processes including development, wound healing, cell-cell signaling, cell growth and differentiation. P-cadherin is expressed in human fetal structures, and in adult tissues such as the basal layer of the epidermis, breast, prostate, ovary, cervix, hair follicle, and corneal endothelium. P-cadherin expression has also been reported on embryonic stem cells, and stem cells of the normal mammary gland, and hair follicle. Overexpression of P-cadherin has been associated with poor prognosis in breast, prostate, ovary, colon, and stomach carcinomas. Mutations in CDH3 are associated with congential hypotrichosis with juvenile macular dystrophy.